HER2-positive breast cancer is characterized by its aggressive nature, poor prognosis, reduced sensitivity to anthracycline-based chemotherapy, and better response to HER2-targeted therapies such as trastuzumab, lapatinib, and pertuzumab [59,60], which significantly improve disease-free and overall survival rates. This evidence concerns the gene ERBB2 and breast cancer.